Acetazolamide Market The Acetazolamide Market is primarily driven by high prevalence of glaucoma, high growth potential in developing countries, and increasing geriatric population worldwide. Acetazolamide is a carbonic anhydrase inhibitor used to treat glaucoma and epilepsy. It helps reduce pressure inside the eye by decreasing fluid production . The Global Acetazolamide Market is estimated to be valued at US$ 303.03 Bn in 2024 and is expected to exhibit a 13% CAGR over the forecast period 2024 To 2031. Key Takeaways Key players operating in the Acetazolamide Market are Merck KgaA, QIAGEN NV, BioMérieux, Illumina Inc., Micronit BV, PerkinElmer Inc., Thermo Fisher Scientific, Fluidigm Corporation, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Abbott Laboratories, Phalanx Biotech Group, and Danaher Corporation (Cepheid), among others. The rising geriatric population and increasing per capita healthcare expenditure in developing countries is expected to drive the demand for acet...